Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Jun;44(6):368-72.
doi: 10.1136/jmg.2006.047464. Epub 2007 Jan 26.

Measurement of the clinical utility of a combined mutation detection protocol in carriers of Duchenne and Becker muscular dystrophy

Peter J Taylor  1 , Sarah Maroulis, Glenda L Mullan, Robyn L Pedersen, Aurora Baumli, George Elakis, Sara Piras, Corrina Walsh, Benito Prósper-Gutiérrez, Fernando De La Puente-Alonso, Christopher G Bell, David R Mowat, Heather M Johnston, Michael F Buckley
Affiliations

Measurement of the clinical utility of a combined mutation detection protocol in carriers of Duchenne and Becker muscular dystrophy

Peter J Taylor et al. J Med Genet. 2007 Jun.

Abstract

Background: Recent methodological advances have improved the detection rate for dystrophin mutations, but there are no published studies that have measured the clinical utility of these protocols for carrier detection compared with conventional carrier testing protocols that use pedigree, serum creatine kinase levels and linkage analysis.

Methods and subjects: The clinical utility of a combined mutation detection protocol was measured. It involved quantitative PCR procedures followed by DNA sequence analysis for the identification of dystrophin mutation carriers in 2101 women at risk of being carriers from 348 mutation-known Duchenne or Becker muscular dystrophy pedigrees.

Results: The combined mutation detection protocol identified a mutation in 96% and 82% of index cases of Duchenne muscular dystrophy and Becker muscular dystrophy, respectively. An additional 692 (33%) potential carriers were correctly classified by the combined mutation detection protocol compared with pedigree, serum creatine kinase levels and linkage analysis. Significantly lower mutation carrier rates were identified in the mothers of isolated cases with deletion mutations than predicted from theoretical considerations, but these findings were not confirmed for duplication and DNA sequence mutations.

Conclusions: There are significant clinical benefits to be gained from a combined mutation detection protocol for carrier detection. It is recommended that mutation-specific carrier frequencies for the different classes of dystrophin mutations should be taken into account in genetic counselling practice.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None.

References

    1. Bushby K, Bourke J, Bullock R, Eagle M, Gibson M, Quinby J. The multidisciplinary management of Duchenne muscular dystrophy. Curr Paediatr 200515292–300.
    1. Chamberlain J S, Gibbs R A, Ranier J E, Caskey C T. Multiplex PCR for the diagnosis of Duchenne muscular dystrophy. In: Innis MA, Gelfand DH, Sninsky JJ, et al eds. PCR protocols: a guide to methods and applications. San Francisco (USA): Academic Press, 1990272–281.
    1. Beggs A H, Koenig M, Boyce F M, Kunkel L M. Detection of 98% of DMD/BMD gene deletions by polymerase chain reaction. Hum Genet 19908645–48. - PubMed
    1. Bakker E, Bonten E J, De Lange L F, Veenema H, Majoor‐Krakauer D, Hofker M H, Van Ommen G J, Pearson P L. DNA probe analysis for carrier detection and prenatal diagnosis of Duchenne muscular dystrophy: a standard diagnostic procedure. J Med Genet 198623573–580. - PMC - PubMed
    1. Clemens P R, Fenwick R G, Chamberlain J S, Gibbs R A, de Andrade M, Chakraborty R, Caskey C T. Carrier detection and prenatal diagnosis in Duchenne and Becker muscular dystrophy families, using dinucleotide repeat polymorphisms. Am J Hum Genet 199149951–960. - PMC - PubMed

Publication types